Poloxamer 188 - Phrixus Pharmaceuticals

Drug Profile

Poloxamer 188 - Phrixus Pharmaceuticals

Alternative Names: Carmeseal; Carmeseal-HF; Carmeseal-MD; P-188; P-188 NF

Latest Information Update: 13 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Phrixus Pharmaceuticals
  • Developer Phrixus Pharmaceuticals; University of Michigan
  • Class Anti-inflammatories; Antithrombotics; Cytoprotectives; Polyethylene glycols; Surfactants
  • Mechanism of Action Blood cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy
  • No development reported Heart failure

Most Recent Events

  • 07 Sep 2016 The US FDA approves IND application filed for Duchenne muscular dystrophy
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Heart-failure in USA (IV)
  • 02 Dec 2014 poloxamer 188 subcutaneous licensed to Ethicor for marketing under European Access Programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top